Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Relapsed/Refractory DLBCL
NCT02038933Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate up to 25 months. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02038933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038933.